Loading organizations...
Based in Cambridge, Massachusetts, Cullinan Therapeutics is a clinical-stage biopharmaceutical company focused on developing targeted therapies for autoimmune diseases and cancer. Formerly known as Cullinan Oncology, the enterprise focuses on high-impact molecules through immune modulation, advancing key clinical programs like zipalertinib for non-small cell lung cancer and CLN-978 for systemic lupus erythematosus and rheumatoid arthritis. The clinical pipeline also includes CLN-619, a monoclonal antibody in Phase 1 trials for solid tumors and multiple myeloma, supported by approximately 110 employees. Following a 2021 initial public offering on the NASDAQ exchange, the publicly traded firm maintains strategic development collaborations with recognizable industry partners including Adimab and Taiho Pharmaceutical. Under Chief Executive Officer Nadim Ahmed, the organization builds upon the scientific foundation established when it was originally incorporated in 2016 by co-founder Dr. Patrick A. Baeuerle.
Cullinan Therapeutics has raised $379.7M across 3 funding rounds.
Cullinan Therapeutics has raised $379.7M in total across 3 funding rounds.
Cullinan Therapeutics has raised $379.7M in total across 3 funding rounds.
Cullinan Therapeutics's investors include Foresite Capital, Baupost Group, Boxer Capital, BVF Partners, Cowen Healthcare Investments, Eventide Asset Management, F2 Ventures, Leerink Partners, Logos Capital, MPM Capital, Nextech Invest, OrbiMed.
Cullinan Therapeutics has raised $379.7M across 3 funding rounds. Most recently, it raised $131.2M Series C in December 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 17, 2020 | $131.2M Series C | Foresite Capital | Baupost Group, Boxer Capital, BVF Partners, Cowen Healthcare Investments, Eventide Asset Management, F2 Ventures, Leerink Partners, Logos Capital, MPM Capital, Nextech Invest, OrbiMed, Rock Springs Capital, Schooner Capital, Venrock | Announced |
| Jun 4, 2020 | $98.5M Series B | — | F2 Ventures, JON Wigginton, MD | Announced |
| Oct 3, 2017 | $150M Series A | F2 Ventures, UBS | — | Announced |
